Therapeutic horizons for amyotrophic lateral sclerosis.
Recent theories on the pathogenesis of motor neuron disease and research on motor neuron injury have resulted in new putative therapies, which include treatment with various neurotrophic factors, antioxidants and anti-excitotoxicity agents. Clinical and preclinical studies have now provided the first agents that reproducibly alter the course of amyotrophic lateral sclerosis.
Rothstein
J D
JD
Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA. jrothste@welchlink.welch.jhu.edu
D000690:Amyotrophic Lateral Sclerosis / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D016472:Motor Neuron Disease / Q000453:epidemiology / Q000628:therapy; D009046:Motor Neurons / Q000473:pathology / Q000502:physiology; D009410:Nerve Degeneration; D009414:Nerve Growth Factors / Q000627:therapeutic use; D009416:Nerve Regeneration; D013482:Superoxide Dismutase / Q000096:biosynthesis / Q000235:genetics
D000975:Antioxidants; D018691:Excitatory Amino Acid Antagonists; D009414:Nerve Growth Factors; D007334:Insulin-Like Growth Factor I; D013482:Superoxide Dismutase